Acutaas Chemicals Ltd. share price target

Management reiterated its FY27 guidance of 25% revenue growth, with EBITDA margins expected to remain in line with FY26 levels. The company also maintains its long-term target of achieving INR 1,000 crore in CDMO revenue by FY28.

Acutaas Chemicals registered healthy growth in Q1FY27 with Revenue, EBITDA and PAT rising by 59%, 122% and 68% respectively. In terms of seasonality Q1 tends to be the softest quarter with a strong ramp up over the financial year. Revenue of Advanced...

Acutaas Chemicals registered a robust performance in Q4FY26. Revenue, EBITDA and PAT registered strong growth of 40%,116% and 111% respectively on YoY terms. We believe the company can clock in PAT CAGR of 28% from FY26-FY28E riding strongly on several growth levers led by the CDMO business. Robust growth in the Fermion contract coupled with steady growth in the NonCDMO Business augur strongly for profitability prospects. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the Ankleshwar unit. We have revised estimates upwards to factor in stronger margin profile. We value...

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 26.6% / 23.1% / 21.2% for the period of FY26-FY28.

Acutaas Chemicals Ltd (formerly Ami Organics), incorporated in 2004, is a leading advanced pharmaceutical intermediates manufacturer (85% FY25 revenue) and specialty chemicals (15%) with a strong presence across CDMO, advanced intermediates and emerging specialty chemistry platforms such as battery chemicals and semiconductor chemicals. The company supports over...

Acutaas Chemicals registered a superlative performance in Q3FY26. Revenue, EBITDA and PAT registered strong growth of 43%,119% and 140% respectively on YoY terms. We believe the company can clock in PAT CAGR of 54% from FY25-FY28E riding strongly on several growth levers led by the CDMO business. Robust growth in the Fermion contract coupled with healthy growth in the NonCDMO Business augur strongly for profitability prospects. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the Ankleshwar unit. We have revised estimates upwards to factor in stronger margin profile. We roll forward...

Strategic Expansion: Battery & semiconductor chemical segments

Acutas Chemicals delivered robust revenue and profit growth, driven by strong performance in API and specialty chemicals segment.

Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...

Acutaas Chemicals registered a strong performance in Q1FY26. Revenue, EBITDA and PAT registered strong growth of 17%,73% and 218% respectively on YoY terms albeit from a weak base. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 23%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with...

Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has announced a strategic investment of up to INR 2 Bn in its wholly owned subsidiary, Acutaas Advance Material Limited (AAML), to support expansion in the semiconductor chemicals business.

AMIORG: Emerging pharma intermediate play; riding on Chinese import substitution. Technology & Internet: Significant jump in FY22 growth guidance

Company benefits from the best of two domains in chemical industry: Pharma intermediates and specialty chemicals

...